Third, we could not compare the efficacy of osimertinib with that of first/second‐generation EGFR‐TKIs, because we do not have statistical data on the use of first/second‐generation EGFR‐TKIs in first‐line treatment of EGFRm+ advanced NSCLC patients in our hospital. Here, EGFR is linked to non-small cell lung carcinoma.